Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated:  5/9/2017
The Mount Sinai Medical Center (New York NY)
mi
from
New York, NY
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated: 5/9/2017
The Mount Sinai Medical Center (New York NY)
mi
from
New York, NY
Click here to add this to my saved trials
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated:  5/9/2017
Cone Health Medical Group HeartCare at Church Street
mi
from
Greensboro, NC
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated: 5/9/2017
Cone Health Medical Group HeartCare at Church Street
mi
from
Greensboro, NC
Click here to add this to my saved trials
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated:  5/9/2017
Raleigh Cardiology Associates
mi
from
Raleigh, NC
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated: 5/9/2017
Raleigh Cardiology Associates
mi
from
Raleigh, NC
Click here to add this to my saved trials
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated:  5/9/2017
Oklahoma Heart Institute
mi
from
Tulsa, OK
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated: 5/9/2017
Oklahoma Heart Institute
mi
from
Tulsa, OK
Click here to add this to my saved trials
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated:  5/9/2017
Diagnostic Cardiology Group
mi
from
Chattanooga, TN
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated: 5/9/2017
Diagnostic Cardiology Group
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated:  5/9/2017
Amarillo Heart Group
mi
from
Amarillo, TX
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated: 5/9/2017
Amarillo Heart Group
mi
from
Amarillo, TX
Click here to add this to my saved trials
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated:  5/9/2017
Texas Cardiac Arrhythmia Research Foundation
mi
from
Austin, TX
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated: 5/9/2017
Texas Cardiac Arrhythmia Research Foundation
mi
from
Austin, TX
Click here to add this to my saved trials
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated:  5/9/2017
Baylor Research Institute (Dallas TX)
mi
from
Dallas, TX
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated: 5/9/2017
Baylor Research Institute (Dallas TX)
mi
from
Dallas, TX
Click here to add this to my saved trials
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated:  5/9/2017
Sentara Norfolk General Hospital
mi
from
Norfolk, VA
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: Enrolling
Updated: 5/9/2017
Sentara Norfolk General Hospital
mi
from
Norfolk, VA
Click here to add this to my saved trials
Diabetic Retinopathy And the Myvisiontrack® (DRAMA) Study
Evaluation of New Self-Test Visual Function Assessment System for Diabetic Retinopathy
Status: Enrolling
Updated:  5/11/2017
Retina Foundation of the Southwest
mi
from
Dallas, TX
Diabetic Retinopathy And the Myvisiontrack® (DRAMA) Study
Evaluation of New Self-Test Visual Function Assessment System for Diabetic Retinopathy
Status: Enrolling
Updated: 5/11/2017
Retina Foundation of the Southwest
mi
from
Dallas, TX
Click here to add this to my saved trials
Diabetic Retinopathy And the Myvisiontrack® (DRAMA) Study
Evaluation of New Self-Test Visual Function Assessment System for Diabetic Retinopathy
Status: Enrolling
Updated:  5/11/2017
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Diabetic Retinopathy And the Myvisiontrack® (DRAMA) Study
Evaluation of New Self-Test Visual Function Assessment System for Diabetic Retinopathy
Status: Enrolling
Updated: 5/11/2017
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
Status: Enrolling
Updated:  5/15/2017
Stanford University School of Medicine
mi
from
Stanford, CA
A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
Status: Enrolling
Updated: 5/15/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
Status: Enrolling
Updated:  5/15/2017
University of Colorado, School of Medicine
mi
from
Aurora, CO
A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
Status: Enrolling
Updated: 5/15/2017
University of Colorado, School of Medicine
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
Status: Enrolling
Updated:  5/15/2017
Johns Hopkins University
mi
from
Baltimore, MD
A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
Status: Enrolling
Updated: 5/15/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
Status: Enrolling
Updated:  5/15/2017
Brigham and Women's Hosp
mi
from
Boston, MA
A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
Status: Enrolling
Updated: 5/15/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
Status: Enrolling
Updated:  5/15/2017
Ohio State University
mi
from
Columbus, OH
A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
Status: Enrolling
Updated: 5/15/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
Status: Enrolling
Updated:  5/15/2017
Meriter Wisconsin Heart
mi
from
Madison, WI
A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
Status: Enrolling
Updated: 5/15/2017
Meriter Wisconsin Heart
mi
from
Madison, WI
Click here to add this to my saved trials
Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI
Randomized Trial of Aggressive Process of Care Quality Improvement Intervention to Decrease Door to Balloon Time in Primary PCI for Acute Myocardial Infarction
Status: Enrolling
Updated:  5/15/2017
University of Michigan
mi
from
Ann Arbor, MI
Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI
Randomized Trial of Aggressive Process of Care Quality Improvement Intervention to Decrease Door to Balloon Time in Primary PCI for Acute Myocardial Infarction
Status: Enrolling
Updated: 5/15/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.
Status: Enrolling
Updated:  5/16/2017
Northwestern University
mi
from
Chicago, IL
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.
Status: Enrolling
Updated: 5/16/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.
Status: Enrolling
Updated:  5/16/2017
University of Michigan Health System
mi
from
Ann Arbor, MI
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.
Status: Enrolling
Updated: 5/16/2017
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.
Status: Enrolling
Updated:  5/16/2017
Ohio State University
mi
from
Columbus, OH
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.
Status: Enrolling
Updated: 5/16/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.
Status: Enrolling
Updated:  5/16/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.
Status: Enrolling
Updated: 5/16/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.
Status: Enrolling
Updated:  5/16/2017
Texas Heart Institute
mi
from
Houston, TX
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.
Status: Enrolling
Updated: 5/16/2017
Texas Heart Institute
mi
from
Houston, TX
Click here to add this to my saved trials
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.
Status: Enrolling
Updated:  5/16/2017
Georgetown Hospital
mi
from
Washington, D.C.,
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.
Status: Enrolling
Updated: 5/16/2017
Georgetown Hospital
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.
Status: Enrolling
Updated:  5/16/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.
Status: Enrolling
Updated: 5/16/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Click here to add this to my saved trials
Effects of Treating Sleep Apnea in Patients With Congestive Heart Failure
Effects of Treating Sleep Apnea in Patients With Congestive Heart Failure
Status: Enrolling
Updated:  5/16/2017
University of Florida
mi
from
Gainesville, FL
Effects of Treating Sleep Apnea in Patients With Congestive Heart Failure
Effects of Treating Sleep Apnea in Patients With Congestive Heart Failure
Status: Enrolling
Updated: 5/16/2017
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy
A Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy for the Treatment of Coronary Artery Disease Using Direct Intramyocardial Administration of an Adenovirus Vector Expressing the VEGF121 cDNA
Status: Enrolling
Updated:  5/23/2017
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy
A Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy for the Treatment of Coronary Artery Disease Using Direct Intramyocardial Administration of an Adenovirus Vector Expressing the VEGF121 cDNA
Status: Enrolling
Updated: 5/23/2017
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy
A Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy for the Treatment of Coronary Artery Disease Using Direct Intramyocardial Administration of an Adenovirus Vector Expressing the VEGF121 cDNA
Status: Enrolling
Updated:  5/23/2017
Weill Cornell Medicine
mi
from
New York, NY
Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy
A Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy for the Treatment of Coronary Artery Disease Using Direct Intramyocardial Administration of an Adenovirus Vector Expressing the VEGF121 cDNA
Status: Enrolling
Updated: 5/23/2017
Weill Cornell Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure
Status: Enrolling
Updated:  5/24/2017
Novartis
mi
from
Denver, CO
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure
Status: Enrolling
Updated: 5/24/2017
Novartis
mi
from
Denver, CO
Click here to add this to my saved trials
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure
Status: Enrolling
Updated:  5/24/2017
Novartis Investigative Site
mi
from
Philadelphia, PA
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure
Status: Enrolling
Updated: 5/24/2017
Novartis Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure
Status: Enrolling
Updated:  5/24/2017
Novartis Investigational Site
mi
from
Charleston, SC
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure
Status: Enrolling
Updated: 5/24/2017
Novartis Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure
Status: Enrolling
Updated:  5/24/2017
Novartis Investigative Site
mi
from
Saint Louis, MO
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure
Status: Enrolling
Updated: 5/24/2017
Novartis Investigative Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure
Status: Enrolling
Updated:  5/24/2017
Novartis Investigative Site
mi
from
The Bronx, NY
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure
Status: Enrolling
Updated: 5/24/2017
Novartis Investigative Site
mi
from
The Bronx, NY
Click here to add this to my saved trials
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure
Status: Enrolling
Updated:  5/24/2017
Novartis Investigative Site
mi
from
Berlin,
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure
Status: Enrolling
Updated: 5/24/2017
Novartis Investigative Site
mi
from
Berlin,
Click here to add this to my saved trials
Deactivation of Implantable Cardioverter Defibrillator During Non-thoracic Surgical Procedures
Deactivation of Implantable Cardioverter Defibrillator During Non-thoracic Surgical Procedures
Status: Enrolling
Updated:  5/30/2017
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Deactivation of Implantable Cardioverter Defibrillator During Non-thoracic Surgical Procedures
Deactivation of Implantable Cardioverter Defibrillator During Non-thoracic Surgical Procedures
Status: Enrolling
Updated: 5/30/2017
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hospital Wearable Defibrillator Inpatient Study
Hospital Wearable Defibrillator Inpatient Study
Status: Enrolling
Updated:  5/30/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Hospital Wearable Defibrillator Inpatient Study
Hospital Wearable Defibrillator Inpatient Study
Status: Enrolling
Updated: 5/30/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Hospital Wearable Defibrillator Inpatient Study
Hospital Wearable Defibrillator Inpatient Study
Status: Enrolling
Updated:  5/30/2017
Clinical Research Facility
mi
from
Danbury, CT
Hospital Wearable Defibrillator Inpatient Study
Hospital Wearable Defibrillator Inpatient Study
Status: Enrolling
Updated: 5/30/2017
Clinical Research Facility
mi
from
Danbury, CT
Click here to add this to my saved trials
Hospital Wearable Defibrillator Inpatient Study
Hospital Wearable Defibrillator Inpatient Study
Status: Enrolling
Updated:  5/30/2017
Clinical Research Facility
mi
from
Jupiter, FL
Hospital Wearable Defibrillator Inpatient Study
Hospital Wearable Defibrillator Inpatient Study
Status: Enrolling
Updated: 5/30/2017
Clinical Research Facility
mi
from
Jupiter, FL
Click here to add this to my saved trials
Hospital Wearable Defibrillator Inpatient Study
Hospital Wearable Defibrillator Inpatient Study
Status: Enrolling
Updated:  5/30/2017
Clinical Research Facility
mi
from
Iowa City, IA
Hospital Wearable Defibrillator Inpatient Study
Hospital Wearable Defibrillator Inpatient Study
Status: Enrolling
Updated: 5/30/2017
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
Hospital Wearable Defibrillator Inpatient Study
Hospital Wearable Defibrillator Inpatient Study
Status: Enrolling
Updated:  5/30/2017
Clinical Research Facility
mi
from
Saint Paul, MN
Hospital Wearable Defibrillator Inpatient Study
Hospital Wearable Defibrillator Inpatient Study
Status: Enrolling
Updated: 5/30/2017
Clinical Research Facility
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Hospital Wearable Defibrillator Inpatient Study
Hospital Wearable Defibrillator Inpatient Study
Status: Enrolling
Updated:  5/30/2017
Clinical Research Facility
mi
from
Richmond, VA
Hospital Wearable Defibrillator Inpatient Study
Hospital Wearable Defibrillator Inpatient Study
Status: Enrolling
Updated: 5/30/2017
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Hospital Wearable Defibrillator Inpatient Study
Hospital Wearable Defibrillator Inpatient Study
Status: Enrolling
Updated:  5/30/2017
Clinical Research Facility
mi
from
Seattle, WA
Hospital Wearable Defibrillator Inpatient Study
Hospital Wearable Defibrillator Inpatient Study
Status: Enrolling
Updated: 5/30/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Hospital Wearable Defibrillator Inpatient Study
Hospital Wearable Defibrillator Inpatient Study
Status: Enrolling
Updated:  5/30/2017
Clinical Research Facility
mi
from
Atlantis, FL
Hospital Wearable Defibrillator Inpatient Study
Hospital Wearable Defibrillator Inpatient Study
Status: Enrolling
Updated: 5/30/2017
Clinical Research Facility
mi
from
Atlantis, FL
Click here to add this to my saved trials
Study With Healthy Japanese and Non-Asian Participants With BMS-986231
A Randomized, Double-Blind, Placebo-controlled, Single Continuous Intravenous Infusion Study of BMS-986231 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Japanese and Non- Asian Participants
Status: Enrolling
Updated:  5/30/2017
West Coast Clinical Trials, LLC
mi
from
Cypress, CA
Study With Healthy Japanese and Non-Asian Participants With BMS-986231
A Randomized, Double-Blind, Placebo-controlled, Single Continuous Intravenous Infusion Study of BMS-986231 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Japanese and Non- Asian Participants
Status: Enrolling
Updated: 5/30/2017
West Coast Clinical Trials, LLC
mi
from
Cypress, CA
Click here to add this to my saved trials
Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients
Vitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan Palliation
Status: Enrolling
Updated:  5/31/2017
University of Michigan
mi
from
Ann Arbor, MI
Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients
Vitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan Palliation
Status: Enrolling
Updated: 5/31/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Investigating Superion™ In Spinal Stenosis
A Prospective, Multi-Center, Randomized Study Comparing the VertiFlex® Superion™ Interspinous Spacer (ISS) to the X-STOP® Interspinous Process Decompression (IPD®) System in Patients With Moderate Lumbar Spinal Stenosis
Status: Enrolling
Updated:  6/6/2017
Arizona Center for Neurosurgery
mi
from
Phoenix, AZ
Investigating Superion™ In Spinal Stenosis
A Prospective, Multi-Center, Randomized Study Comparing the VertiFlex® Superion™ Interspinous Spacer (ISS) to the X-STOP® Interspinous Process Decompression (IPD®) System in Patients With Moderate Lumbar Spinal Stenosis
Status: Enrolling
Updated: 6/6/2017
Arizona Center for Neurosurgery
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Investigating Superion™ In Spinal Stenosis
A Prospective, Multi-Center, Randomized Study Comparing the VertiFlex® Superion™ Interspinous Spacer (ISS) to the X-STOP® Interspinous Process Decompression (IPD®) System in Patients With Moderate Lumbar Spinal Stenosis
Status: Enrolling
Updated:  6/6/2017
Tucson Orthopaedic Institute
mi
from
Tucson, AZ
Investigating Superion™ In Spinal Stenosis
A Prospective, Multi-Center, Randomized Study Comparing the VertiFlex® Superion™ Interspinous Spacer (ISS) to the X-STOP® Interspinous Process Decompression (IPD®) System in Patients With Moderate Lumbar Spinal Stenosis
Status: Enrolling
Updated: 6/6/2017
Tucson Orthopaedic Institute
mi
from
Tucson, AZ
Click here to add this to my saved trials
Investigating Superion™ In Spinal Stenosis
A Prospective, Multi-Center, Randomized Study Comparing the VertiFlex® Superion™ Interspinous Spacer (ISS) to the X-STOP® Interspinous Process Decompression (IPD®) System in Patients With Moderate Lumbar Spinal Stenosis
Status: Enrolling
Updated:  6/6/2017
D.I.S.C. Sports and Spine Center
mi
from
Beverly Hills, CA
Investigating Superion™ In Spinal Stenosis
A Prospective, Multi-Center, Randomized Study Comparing the VertiFlex® Superion™ Interspinous Spacer (ISS) to the X-STOP® Interspinous Process Decompression (IPD®) System in Patients With Moderate Lumbar Spinal Stenosis
Status: Enrolling
Updated: 6/6/2017
D.I.S.C. Sports and Spine Center
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Investigating Superion™ In Spinal Stenosis
A Prospective, Multi-Center, Randomized Study Comparing the VertiFlex® Superion™ Interspinous Spacer (ISS) to the X-STOP® Interspinous Process Decompression (IPD®) System in Patients With Moderate Lumbar Spinal Stenosis
Status: Enrolling
Updated:  6/6/2017
Tower Orthopaedics and Sports Medicine/ Institute for Advanced Spinal Research
mi
from
Beverly Hills, CA
Investigating Superion™ In Spinal Stenosis
A Prospective, Multi-Center, Randomized Study Comparing the VertiFlex® Superion™ Interspinous Spacer (ISS) to the X-STOP® Interspinous Process Decompression (IPD®) System in Patients With Moderate Lumbar Spinal Stenosis
Status: Enrolling
Updated: 6/6/2017
Tower Orthopaedics and Sports Medicine/ Institute for Advanced Spinal Research
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Investigating Superion™ In Spinal Stenosis
A Prospective, Multi-Center, Randomized Study Comparing the VertiFlex® Superion™ Interspinous Spacer (ISS) to the X-STOP® Interspinous Process Decompression (IPD®) System in Patients With Moderate Lumbar Spinal Stenosis
Status: Enrolling
Updated:  6/6/2017
Brain and Spine Research Institute
mi
from
Los Angeles, CA
Investigating Superion™ In Spinal Stenosis
A Prospective, Multi-Center, Randomized Study Comparing the VertiFlex® Superion™ Interspinous Spacer (ISS) to the X-STOP® Interspinous Process Decompression (IPD®) System in Patients With Moderate Lumbar Spinal Stenosis
Status: Enrolling
Updated: 6/6/2017
Brain and Spine Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials